Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners and 5 distinct art units, showing that every listed matter is assigned through a separate examination channel.
WHITE, DAWANNA SHAR-DAY is the busiest examiner, with 1 pending matter. The workload is distributed across the portfolio, so counsel should organize prosecution by individual file and art-unit issues rather than rely on a common examiner strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §102 only | 1 (17%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| BAUER, NICOLA MARIA | 1 | 58.7% | +52.1% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017666 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | 71d |
| 18833879 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18723812 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JACKSON, SHAWQUIA | — |
| 18685883 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BAUER, NICOLA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17596239 | ANTI-B7-H4 ANTIBODY-DRUG CONJUGATE AND MEDICINAL USE THEREOF | PUTTLITZ, KARL J | 34d |
| 18017666 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | 71d |
| 18833879 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18685883 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BAUER, NICOLA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1626 | 1 |
| 1621 | 1 |
| 1625 | 1 |
| 1629 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833879 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | 1627 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18723812 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JACKSON, SHAWQUIA | 1626 | §102§112 | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18685883 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BAUER, NICOLA MARIA | 1621 | §102§103 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18551180 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SEAMAN, D MARGARET M | 1625 | §102 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18017666 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Final Rejection | 71d | Pending | Jan 23, 2023 |
| 17596239 | ANTI-B7-H4 ANTIBODY-DRUG CONJUGATE AND MEDICINAL USE THEREOF | PUTTLITZ, KARL J | 1646 | §103 | Non-Final OA | 34d | Pending | Dec 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJiangsu Hansoh Pharmaceutical Group Co. Ltd. has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Dawanna Shar-Day White has the most, with 1 of Jiangsu Hansoh Pharmaceutical Group Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
